"I am consistently impressed by Natera and its mission, and I am confident that our current initiatives will continue to positively transform women's health, oncology and transplant," said
As previously announced, Natera's executive leaders and non-employee directors have elected to take 100% equity compensation for the remainder of 2022. In addition, in
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that the plans, estimates, or expectations contained in such forward-looking statements will be achieved. These forward-looking statements represent expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: Natera faces numerous uncertainties and challenges in achieving its financial projections and goals; Natera's quarterly results and stock price may fluctuate from period to period; Natera's estimates of market opportunity and forecasts of market growth may prove to be inaccurate; Natera may be unable to compete successfully with existing or future products or services offered by its competitors; Natera may be unable to develop and successfully commercialize new products; and Natera's existing and any new products may not meet the expectations of patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the
Contacts
Investor Relations:
Media:
View original content to download multimedia:https://www.prnewswire.com/news-releases/matthew-rabinowitz-natera-co-founder-and-executive-chairman-of-the-board-makes-additional-investment-in-natera-301547776.html
SOURCE
"I am consistently impressed by Natera and its mission, and I am confident that our current initiatives will continue to positively transform women's health, oncology and transplant," said
As previously announced, Natera's executive leaders and non-employee directors have elected to take 100% equity compensation for the remainder of 2022. In addition, in
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that the plans, estimates, or expectations contained in such forward-looking statements will be achieved. These forward-looking statements represent expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: Natera faces numerous uncertainties and challenges in achieving its financial projections and goals; Natera's quarterly results and stock price may fluctuate from period to period; Natera's estimates of market opportunity and forecasts of market growth may prove to be inaccurate; Natera may be unable to compete successfully with existing or future products or services offered by its competitors; Natera may be unable to develop and successfully commercialize new products; and Natera's existing and any new products may not meet the expectations of patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the
Contacts
Investor Relations:
Media:
View original content to download multimedia:https://www.prnewswire.com/news-releases/matthew-rabinowitz-natera-co-founder-and-executive-chairman-of-the-board-makes-additional-investment-in-natera-301547776.html
SOURCE